AdaptHealth Q2 net loss $145.3M; revises FY2026 guidance down; divests Diabetes Health for $235M

AdaptHealth Corp.

Net revenue $740.3M (+12.7% YoY); organic growth 15.9%; net loss $145.3M vs net income $4.2M in prior year.
Adjusted EBITDA $132.0M, down 3.2% YoY; includes $144.2M pre-tax goodwill impairment.
FY2026 guidance revised: revenue $2.85-2.89B, Adj. EBITDA $490-520M, free cash flow $80-120M (from prior $680-730M Adj. EBITDA).
Definitive agreement to sell Diabetes Health business for $235M cash; presented as discontinued operations.
New capitated agreements: West Coast IDN at run-rate; Humana OneHome in FL/TX for ~478K members.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.